Status:
COMPLETED
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Unspecified Adult Solid Tumor, Protocol Specific
Eligibility:
All Genders
18-120 years
Phase:
PHASE1
Brief Summary
RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the gr...
Detailed Description
OBJECTIVES: Primary * To determine the safety, tolerability, maximum tolerated dose (MTD), and recommended phase II dose of panobinostat when administered with epirubicin hydrochloride in patients w...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Cytologically or histologically confirmed solid tumor malignancy for which no curative therapy exists
- Metastatic disease
- Measurable or evaluable disease (i.e., elevated CA-125 or elevated PSA for patients with ovarian cancer or prostate cancer, respectively)
- Disease amenable to biopsy AND patient willing to undergo biopsies (for patients enrolled in the dose expansion cohort only)
- No uncontrolled CNS metastasis
- Stable CNS metastasis allowed provided patient has undergone complete surgical resection, gamma knife radiotherapy (for isolated lesions) or whole-brain radiotherapy AND the metastasis has been stable for ≥ 6 weeks
- PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- WBC \> 3,000/mm³
- ANC \> 1,500/mm³
- Hemoglobin \> 9.0 g/dL (RBC transfusion allowed)
- Platelet count \> 100,000/mm³
- AST/ALT ≤ 1.5 times upper limit of normal (ULN)
- Serum bilirubin ≤ 1.3 times ULN
- Serum creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 50 mL/min by 24-hour urine collection
- Total serum calcium (corrected for serum albumin) or ionized calcium ≥ lower limit of normal
- Serum potassium ≥ 4.0 mEq/L (supplementation allowed)
- Serum magnesium normal (supplementation allowed)
- Serum sodium ≥ 130 mEq/L
- Serum albumin ≥ 3 g/dL
- Elevated alkaline phosphatase or gamma-glutamyl-transferase due to bone metastasis or liver metastasis allowed
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective double-method (including barrier) contraception during and for 3 months after completion of study treatment
- QTc \< 460 ms
- No evidence of significant active infection (e.g., pneumonia, cellulitis, or wound abscess)
- No impaired cardiac function, including any of the following:
- Complete left bundle branch block or use of a permanent cardiac pacemaker
- Congenital long QT syndrome
- History or presence of ventricular tachyarrhythmias
- Clinically significant resting bradycardia (\< 50 beats per minute)
- QTcF \> 470 msec on screening ECG
- Right bundle branch block plus left anterior hemiblock (bifascicular block)
- Atrial fibrillation (ventricular heart rate \> 100 beats per minute)
- Angina pectoris or acute myocardial infarction within the past 6 months
- New York Heart Association class III-IV congestive heart failure
- LVEF \< 50% on baseline MUGA or ECHO
- No history of seizures
- PRIOR CONCURRENT THERAPY:
- No prior cumulative anthracycline dose \> 300 mg/m² of doxorubicin hydrochloride or \> 480 mg/m² of epirubicin hydrochloride
- More than 5 days since prior valproic acid
- More than 3 weeks since prior and no other concurrent chemotherapy, hormonal therapy, radiotherapy, or experimental anticancer therapy for the primary disease
- No other concurrent HDAC inhibitors
- No concurrent medications that may induce torsades de pointes or cause QTc prolongation
- No other concurrent investigational or anticancer therapy
- No concurrent CYP3A4 inhibitors (including grapefruit or grapefruit juice) and/or CYP3A4 inducers
- No concurrent anti-arrhythmic therapy
Exclusion
Key Trial Info
Start Date :
September 13 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 10 2016
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00878904
Start Date
September 13 2009
End Date
October 10 2016
Last Update
March 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94143-1711